ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000B30

Human embryonic stem cell technology : large scale cell amplification and differentiation

Identifieur interne : 000B30 ( PascalFrancis/Corpus ); précédent : 000B29; suivant : 000B31

Human embryonic stem cell technology : large scale cell amplification and differentiation

Auteurs : Steve K. W. Oh ; Andre B. H. Choo

Source :

Cytotechnology : (Dordrecht) [ 0920-9069 ] ; 2006.

RBID : Pascal:06-0448821

Descripteurs français

Pascal (Inist)
- Homme, Embryon, Cellule souche, Cytodifférenciation, Amplification, Bioréacteur, Dimensionnement, Milieu sans sérum, Culture.

English descriptors

KwdEn :
- Amplification, Bioreactor, Cell differentiation, Culture, Dimensioning, Embryo, Human, Serum free medium, Stem cell.

Abstract

Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson's Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of 'defined' feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0920-9069`
A03		`1`		`@0 Cytotechnology : (Dordr.)`
A05				`@2 50`
A06				`@2 1-3`
A08	`01`	`1`	`ENG`	`@1 Human embryonic stem cell technology : large scale cell amplification and differentiation`
A09	`01`	`1`	`ENG`	`@1 Animal Cell Culture Technology - Past, Present, and Future`
A11	`01`	`1`		`@1 OH (Steve K. W.)`
A11	`02`	`1`		`@1 CHOO (Andre B. H.)`
A12	`01`	`1`		`@1 MERTEN (Otto) @9 ed.`
A14	`01`			`@1 Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros @2 Singapore 138668 @3 SGP @Z 1 aut. @Z 2 aut.`
A15	`01`			`@1 Gene Therapy Program, A.F.M.-Genethon III, 1 rue de l'Internationale, BP 60 @2 91002 Evry @3 FRA @Z 1 aut.`
A20				`@1 181-190`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21360 @5 354000133335060110`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.3/4`
A47	`01`	`1`		`@0 06-0448821`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Cytotechnology : (Dordrecht)`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson's Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of 'defined' feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities.
C02	`01`	`X`		`@0 002A`
C03	`01`	`X`	`FRE`	`@0 Homme @5 01`
C03	`01`	`X`	`ENG`	`@0 Human @5 01`
C03	`01`	`X`	`SPA`	`@0 Hombre @5 01`
C03	`02`	`X`	`FRE`	`@0 Embryon @5 02`
C03	`02`	`X`	`ENG`	`@0 Embryo @5 02`
C03	`02`	`X`	`SPA`	`@0 Embrión @5 02`
C03	`03`	`X`	`FRE`	`@0 Cellule souche @5 10`
C03	`03`	`X`	`ENG`	`@0 Stem cell @5 10`
C03	`03`	`X`	`SPA`	`@0 Célula primitiva @5 10`
C03	`04`	`X`	`FRE`	`@0 Cytodifférenciation @5 11`
C03	`04`	`X`	`ENG`	`@0 Cell differentiation @5 11`
C03	`04`	`X`	`SPA`	`@0 Diferenciación celular @5 11`
C03	`05`	`X`	`FRE`	`@0 Amplification @5 12`
C03	`05`	`X`	`ENG`	`@0 Amplification @5 12`
C03	`05`	`X`	`SPA`	`@0 Amplificación @5 12`
C03	`06`	`X`	`FRE`	`@0 Bioréacteur @5 19`
C03	`06`	`X`	`ENG`	`@0 Bioreactor @5 19`
C03	`06`	`X`	`SPA`	`@0 Biorreactor @5 19`
C03	`07`	`X`	`FRE`	`@0 Dimensionnement @5 20`
C03	`07`	`X`	`ENG`	`@0 Dimensioning @5 20`
C03	`07`	`X`	`SPA`	`@0 Dimensionamiento @5 20`
C03	`08`	`X`	`FRE`	`@0 Milieu sans sérum @5 21`
C03	`08`	`X`	`ENG`	`@0 Serum free medium @5 21`
C03	`08`	`X`	`SPA`	`@0 Medio sin suero @5 21`
C03	`09`	`X`	`FRE`	`@0 Culture @5 22`
C03	`09`	`X`	`ENG`	`@0 Culture @5 22`
C03	`09`	`X`	`SPA`	`@0 Cultivo @5 22`
N21				`@1 296`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0448821 INIST
ET :	Human embryonic stem cell technology : large scale cell amplification and differentiation
AU :	OH (Steve K. W.); CHOO (Andre B. H.); MERTEN (Otto)
AF :	Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros/Singapore 138668/Singapour (1 aut., 2 aut.); Gene Therapy Program, A.F.M.-Genethon III, 1 rue de l'Internationale, BP 60/91002 Evry/France (1 aut.)
DT :	Publication en série; Niveau analytique
SO :	Cytotechnology : (Dordrecht); ISSN 0920-9069; Pays-Bas; Da. 2006; Vol. 50; No. 1-3; Pp. 181-190; Bibl. 1 p.3/4
LA :	Anglais
EA :	Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson's Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of 'defined' feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities.
CC :	002A
FD :	Homme; Embryon; Cellule souche; Cytodifférenciation; Amplification; Bioréacteur; Dimensionnement; Milieu sans sérum; Culture
ED :	Human; Embryo; Stem cell; Cell differentiation; Amplification; Bioreactor; Dimensioning; Serum free medium; Culture
SD :	Hombre; Embrión; Célula primitiva; Diferenciación celular; Amplificación; Biorreactor; Dimensionamiento; Medio sin suero; Cultivo
LO :	INIST-21360.354000133335060110
ID :	06-0448821

Links to Exploration step

Pascal:06-0448821

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Human embryonic stem cell technology : large scale cell amplification and differentiation</title>
<author><name sortKey="Oh, Steve K W" sort="Oh, Steve K W" uniqKey="Oh S" first="Steve K. W." last="Oh">Steve K. W. Oh</name>
<affiliation><inist:fA14 i1="01"><s1>Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros</s1>
<s2>Singapore 138668</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Choo, Andre B H" sort="Choo, Andre B H" uniqKey="Choo A" first="Andre B. H." last="Choo">Andre B. H. Choo</name>
<affiliation><inist:fA14 i1="01"><s1>Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros</s1>
<s2>Singapore 138668</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0448821</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0448821 INIST</idno>
<idno type="RBID">Pascal:06-0448821</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B30</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Human embryonic stem cell technology : large scale cell amplification and differentiation</title>
<author><name sortKey="Oh, Steve K W" sort="Oh, Steve K W" uniqKey="Oh S" first="Steve K. W." last="Oh">Steve K. W. Oh</name>
<affiliation><inist:fA14 i1="01"><s1>Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros</s1>
<s2>Singapore 138668</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Choo, Andre B H" sort="Choo, Andre B H" uniqKey="Choo A" first="Andre B. H." last="Choo">Andre B. H. Choo</name>
<affiliation><inist:fA14 i1="01"><s1>Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros</s1>
<s2>Singapore 138668</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cytotechnology : (Dordrecht)</title>
<title level="j" type="abbreviated">Cytotechnology : (Dordr.)</title>
<idno type="ISSN">0920-9069</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cytotechnology : (Dordrecht)</title>
<title level="j" type="abbreviated">Cytotechnology : (Dordr.)</title>
<idno type="ISSN">0920-9069</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amplification</term>
<term>Bioreactor</term>
<term>Cell differentiation</term>
<term>Culture</term>
<term>Dimensioning</term>
<term>Embryo</term>
<term>Human</term>
<term>Serum free medium</term>
<term>Stem cell</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Embryon</term>
<term>Cellule souche</term>
<term>Cytodifférenciation</term>
<term>Amplification</term>
<term>Bioréacteur</term>
<term>Dimensionnement</term>
<term>Milieu sans sérum</term>
<term>Culture</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson's Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of 'defined' feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0920-9069</s0>
</fA01>
<fA03 i2="1"><s0>Cytotechnology : (Dordr.)</s0>
</fA03>
<fA05><s2>50</s2>
</fA05>
<fA06><s2>1-3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Human embryonic stem cell technology : large scale cell amplification and differentiation</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Animal Cell Culture Technology - Past, Present, and Future</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>OH (Steve K. W.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CHOO (Andre B. H.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>MERTEN (Otto)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros</s1>
<s2>Singapore 138668</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Gene Therapy Program, A.F.M.-Genethon III, 1 rue de l'Internationale, BP 60</s1>
<s2>91002 Evry</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20><s1>181-190</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21360</s2>
<s5>354000133335060110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0448821</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Cytotechnology : (Dordrecht)</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson's Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of 'defined' feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Embryon</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Embryo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Embrión</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Cellule souche</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Stem cell</s0>
<s5>10</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Célula primitiva</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cytodifférenciation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cell differentiation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Diferenciación celular</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Amplification</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Amplification</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Amplificación</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Bioréacteur</s0>
<s5>19</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Bioreactor</s0>
<s5>19</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Biorreactor</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Dimensionnement</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dimensioning</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Dimensionamiento</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Milieu sans sérum</s0>
<s5>21</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Serum free medium</s0>
<s5>21</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Medio sin suero</s0>
<s5>21</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Culture</s0>
<s5>22</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Culture</s0>
<s5>22</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cultivo</s0>
<s5>22</s5>
</fC03>
<fN21><s1>296</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0448821 INIST</NO>
<ET>Human embryonic stem cell technology : large scale cell amplification and differentiation</ET>
<AU>OH (Steve K. W.); CHOO (Andre B. H.); MERTEN (Otto)</AU>
<AF>Stem Cell Group, Bioprocessing Technology Institute, 20 Biopolis Way, #06 - 01 Centros/Singapore 138668/Singapour (1 aut., 2 aut.); Gene Therapy Program, A.F.M.-Genethon III, 1 rue de l'Internationale, BP 60/91002 Evry/France (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Cytotechnology : (Dordrecht); ISSN 0920-9069; Pays-Bas; Da. 2006; Vol. 50; No. 1-3; Pp. 181-190; Bibl. 1 p.3/4</SO>
<LA>Anglais</LA>
<EA>Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson's Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of 'defined' feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities.</EA>
<CC>002A</CC>
<FD>Homme; Embryon; Cellule souche; Cytodifférenciation; Amplification; Bioréacteur; Dimensionnement; Milieu sans sérum; Culture</FD>
<ED>Human; Embryo; Stem cell; Cell differentiation; Amplification; Bioreactor; Dimensioning; Serum free medium; Culture</ED>
<SD>Hombre; Embrión; Célula primitiva; Diferenciación celular; Amplificación; Biorreactor; Dimensionamiento; Medio sin suero; Cultivo</SD>
<LO>INIST-21360.354000133335060110</LO>
<ID>06-0448821</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B30 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B30 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0448821
   |texte=   Human embryonic stem cell technology : large scale cell amplification and differentiation
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Human embryonic stem cell technology : large scale cell amplification and differentiation

Human embryonic stem cell technology : large scale cell amplification and differentiation

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri